Pipeline

One platform. Multiple programs. Each one targeting a condition that needs better options.

PIPELINE

Introduction

Because all of EPIK’s medicines are built on the same foundational platform, each new program benefits from the work done on the others. Safety data carries over. Development timelines are shorter. And each program can advance independently.

Our Programs

The following programs are currently in preclinical development (animal testing phase), with human clinical trials targeted for early to mid 2027.

  • EPK 001- preclinical (animal testing)
  • EPK 002- R&D with planned preclinical animal testing Fall 2026
  • EPK 003- R&D with planned preclinical animal testing Fall 2026
  • EPK 004-006 – Discovery
Roadmap

Development Roadmap

  • Q1 2026 – Animal testing and pharmacokinetic studies underway
  • Q2 2026 – LabCorp delivers three medicine blends and five-plus delivery systems
  • May 2026 – Global public relations campaign launches
  • Summer 2026 – Strategic partnership outreach to major biotech companies
    Path to Going Public, ticker EPIK already reserved on Nasdaq
  • Early to mid 2027 – Human Phase 1 clinical trials begin
Compares

How EPIK Stands Apart in the Psychedelic Medicine Space

The psychedelic medicine space has attracted significant investment and validation. Companies like Delfinium (MindMed), Compass Pathways, and ATAI Life Sciences are all valued at over one billion dollars before receiving FDA approval. The sector as a whole exceeds ten billion dollars in aggregate value.

EPIK is pursuing the same therapeutic goal as these companies — but with a fundamentally different and lower-risk approach:

  • Work with Schedule 1 controlled substances (psilocybin, MDMA) — EPIK does not
  • Require clinic-based treatment — EPIK is primarily home-use
  • Have faced longer, more expensive regulatory timelines — EPIK’s expected 505(b)(2) path or expedited process is faster and less costly
  • In August 2025, Gilgamesh Pharmaceuticals — a competitor — was acquired for 1.2 billion dollars, validating the sector’s commercial potential